exploring available third-line treatment options for r/r dlbcl: car-t, bispecifics, adcs & mabs
Published 1 year ago • 100 plays • Length 2:49Download video MP4
Download video MP3
Similar videos
-
4:10
the use of adcs & bispecific antibodies before and after car-t therapy in third-line dlbcl
-
2:52
current immunotherapeutic approaches in dlbcl: the value of car-t cells and bispecific antibodies
-
2:05
strategies to implement car-t in dlbcl
-
1:20
limitations of car t-cell therapy for dlbcl
-
2:34
car-t & bispecific antibodies in second-line dlbcl
-
3:43
safety and efficacy of ytb323, a car t-cell therapy, in r/r dlbcl
-
1:31
the current state of treatment for limited-stage dlbcl
-
31:30
cd20 x cd3 bispecifics—redefining treatment for patients with r/r dlbcl/lbcl in the community set...
-
6:23
the benefits of bispecific antibodies over car-t cell therapy in lymphoma
-
29:38
dlbcl treatment approaches: what you need to know
-
3:01
how the treatment of dlbcl and fl are changing in the uk
-
1:53
the current immunotherapeutic landscape for treatment of dlbcl
-
4:00
current treatment landscape of dlbcl
-
1:01
impact of specific comorbidities on the outcome of patients with dlbcl treated with car-t therapy
-
2:55
car t-cell update: what’s new in dlbcl and mm?
-
5:40
optimization of pet scans and determining relapse in dlbcl
-
38:51
monoclonal antibodies and their role in dlbcl treatment
-
4:45
what is lymphodepleting chemotherapy?
-
1:21
is there a cure for diffuse large b-cell lymphoma? #dlbcl
-
1:49
updates in the dlbcl treatment landscape
-
10:41
car t-cell case study: sequencing therapies for patients with high-risk dlbcl
-
21:56
what's new in the approach to dlbcl upfront and in the relapsed setting beyond car t